Mario Romeo | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Mario Romeo | Precision Medicine | Best Researcher Award

Dr. Mario Romeo, Dipartimento di Medicina di Precisione, Università degli Studi della Campania, LuigiVanvitelli, Italy

Dr. Mario Romeo is an accomplished medical doctor and researcher specializing in Digestive System Diseases. Graduating with top honors in Medicine and Surgery from the University of Campania “Luigi Vanvitelli” 🎓, he also earned a specialization in Gastroenterology and is pursuing a Ph.D. in Clinical and Experimental Medical Sciences. His research spans gut microbiota 🧫, liver disease 🏥, and metabolic dysfunction. A recipient of over 20 international awards 🏆, Dr. Romeo is widely recognized for his groundbreaking work in hepatology and gastroenterology. He actively contributes to scientific societies and fosters innovation in digestive health care.

Publication Profile 

Orcid

Education

Dr. Mario Romeo 🎓 began his academic journey with honors, earning his Diploma di Maturità Classica from Liceo Classico Gneo Nevio in June 2014 with a perfect score of 100/100 con lode 📜. He continued his excellence at the University of Campania “Luigi Vanvitelli,” completing his Laurea in Medicina e Chirurgia in July 2020 with 110/110 con lode 🩺, presenting a thesis on sarcopenia in compensated liver cirrhosis. He further specialized in Digestive System Diseases, earning his diploma in January 2025 with 50/50 con lode 🌟. His thesis explored RPR as a non-invasive tool in liver disease prediction.

Awards

Dr. Mario Romeo 🏅 has received numerous prestigious scholarships and awards in recognition of his excellence in hepatology and gastroenterology. Highlights include competitive fellowships like the AISF MasterClass 2022 🎓 and UEG Clinical Visiting Fellowship 2025 🌍. He has earned multiple travel grants ✈️ and best presentation prizes 🏆 at top events such as UEG Week, FISMAD, EASL, and ESCI for groundbreaking research on liver diseases, MAFLD, gut microbiota, and non-invasive biomarkers. His multidisciplinary “CoCoNut” protocol 🍏 also gained international acclaim. These accolades affirm his dynamic role in advancing liver research and patient care through innovation and collaboration.

Research Focus 

Dr. Mario Romeo’s research focus lies predominantly in Hepatology and Gastroenterology, with a strong emphasis on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), liver cirrhosis, and gut-liver axis dynamics 🧬🍽️. His work explores non-invasive biomarkers, body composition, oxidative stress, and gut microbiota 🧫, highlighting their roles in disease progression and clinical outcomes. He also investigates multidisciplinary management strategies combining nutritional, psychological, and pharmacological interventions 🥗🧠💊. Dr. Romeo contributes significantly to understanding liver-related complications like sarcopenia, dysgeusia, and hepatocellular carcinoma 🎯. His innovative, patient-centered research enhances predictive diagnostics and therapeutic approaches in chronic liver diseases.

Publication Top Notes

  • Spleen Area Affects the Performance of the Platelet Count–Based Non-invasive Tools in Predicting First Hepatic Decompensation in Metabolic Dysfunction–Associated Steatotic Liver Disease Cirrhosis
  • Nutritional and Psychological Support as a Multidisciplinary Coordinated Approach in the Management of Chronic Liver Disease: A Scoping Review
  • Letter: Different Risk of Acute Variceal Bleeding According to the Liver Disease Aetiology in Decompensated Cirrhosis Patients Receiving Carvedilol‐Based Primary Prophylaxis—May Insulin Resistance Unloose This Gordian Knot?
  • Exploring the Classic and Novel Pathogenetic Insights of Plastic Exposure in the Genesis and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • The Role of the Gut–Biliary–Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications
  • Primary biliary cholangitis, Celiac Disease, and MASLD: the triumvirate of steatosis. How should we manage this triple overlap?
  • Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?
  • FLAME: Training and Validating a Newly Conceived Model Incorporating Alpha-Glutathione-S-Transferase Serum Levels for Predicting Advanced Hepatic Fibrosis and Acute Cardiovascular Events in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Dysgeusia in MASLD-related advanced chronic liver disease (ACLD): a silent driver towards the “Bermuda” triangle of malnutrition-sarcopenia-frailty severely affecting prognosis
  • Vanek’s Tumour as a Rare Cause of Dyspeptic Syndrome in a Patient with Primary Biliary Cholangitis: A Case Report
  • Systemic Oxidative Stress Correlates with Sarcopenia and Pruritus Severity in Primary Biliary Cholangitis (PBC): Two Independent Relationships Simultaneously Impacting the Quality of Life—Is the Low Absorption of Cholestasis-Promoted Vitamin D a Puzzle Piece?
  • Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study

Hui Huang | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Hui Huang | Precision Medicine | Best Researcher Award

Prof. Dr. Hui Huang, The Eighth Affiliated Hospital of Sun Yat-Sen University, China

Prof. Hui Huang is Vice President of The Eighth Affiliated Hospital of Sun Yat-sen University and a renowned expert in vascular calcification and chronic disease prevention. 📚 He has authored 100+ high-impact papers in journals like Circulation and J Clin Invest, earning honors like ESI Highly Cited and Top 100 High-Value Papers. 🏆 A recipient of China’s Excellent Young Scientists Fund, he directs multiple prestigious laboratories and holds several international patents. 🔬 His research explores metabolic and immune mechanisms in chronic kidney disease and vascular aging.

Publication Profile

Scopus

Education

Prof. Dr. Hui Huang has authored over 100 peer-reviewed papers in prestigious journals such as Circulation (2022, 2023), J Clin Invest. (2021, 2022, 2025), Hypertension (2018, 2021, 2022), STTT (2022–2024), Kidney Int. (2024), and Cardiovasc Res. (2023) 📚. His impactful work has earned distinctions like ESI Highly Cited Papers, Top 100 High-Value Papers, and journal Cover Stories 🏅. A recipient of China’s National Science Fund for Excellent Young Scholars 🎓, he also led the development of the Expert Consensus on Vascular Calcification, offering vital clinical guidance for practitioners in the field of cardiovascular and renal medicine ❤️🩺.

Experience

Prof. Dr. Hui Huang has led more than 13 major research projects, predominantly funded by the National Natural Science Foundation of China (NSFC) 🔬🇨🇳. His groundbreaking work focuses on unraveling the innovative mechanisms behind arterial calcification, chronic kidney disease, and inflammation 🧠🫀. These projects are long-term, high-budget, and scientifically robust, highlighting their critical importance on both national and global stages 🌍💰. Through his pioneering research, Prof. Huang is driving transformative advancements in cardiovascular and renal health, contributing significantly to medical science and improving patient outcomes 🚀🩺.

Research Focus

Prof. Dr. Hui Huang is a leading researcher in biomedical sciences, with a strong focus on cardiovascular disease, immunology, toxicology, and metabolic disorders. Her work spans areas such as inflammation in the central nervous system, myocardial infarction, diabetes-related metabolomics, and environmental health risks like metal toxicity. 🌡️🧠🫀 She also explores digital therapeutics and sex-based differences in disease outcomes, making her contributions highly interdisciplinary. 📊💻 Her research integrates clinical, molecular, and environmental insights to develop novel strategies for disease prevention and treatment. A strong advocate for translational medicine, Prof. Huang bridges lab science with real-world health challenges.

Publication Top Notes

The Innate Immune Sensor Zbp1 Mediates Central Nervous System Inflammation Induced by Angiostrongylus Cantonensis by Promoting Macrophage Inflammatory Phenotypes

Targeted LC-MS/MS method of oxylipin profiling reveals differentially expressed serum metabolites in type 2 diabetes mice with panaxynol

Ellagic acid-enhanced biocompatibility and bioactivity in multilayer core-shell gold nanoparticles for ameliorating myocardial infarction injury

Sex difference in human diseases: mechanistic insights and clinical implications

Effect of plateletcrit and methylenetetrahydrofolate reductase (MTHFR) C677T genotypes on folic acid efficacy in stroke prevention

Digital therapeutics in hypertension: How to make sustainable lifestyle changes

Associations of essential metals with the risk of aortic arch calcification: a cross-sectional study in a mid-aged and older population of Shenzhen, China

Michael Harrison | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Michael Harrison | Precision Medicine | Best Researcher Award

Dr. Michael Harrison, UCSF, United States

Dr. Michael Harrison is a pioneering pediatric surgeon and fetal therapy expert. 🎓 He earned his B.A. from Yale (1965) and M.D. from Harvard Medical School (1969), followed by extensive surgical training at Massachusetts General Hospital and fellowships in pediatric surgery. 🏥 He joined UCSF in 1978, where he became a Full Professor and founded the Fetal Treatment Center. 👶 His groundbreaking work in fetal surgery has earned him numerous accolades, including the Golden Plate Award and presidency of the International Fetal Medicine and Surgery Society. 🌍 Now Professor Emeritus at UCSF, he continues to shape the field of pediatric surgery. ✨

Publication Profile

Scopus

Education

Dr. Michael Harrison 🎓 began his academic journey at Yale University (1961-1965), earning a B.A. before pursuing his M.D. in Medicine at Harvard Medical School (1965-1969) 🏥. He completed his surgical residency at Massachusetts General Hospital (1969-1971) and advanced his expertise as a Postdoctoral Fellow in Allergy & Immunology at the National Institute of Allergy and Infectious Disease (1971-1973) 🧬. Returning to Massachusetts General, he served as a Senior Resident (1973-1974) and Chief Resident (1974-1975) 🔬. Further specializing, he completed fellowships in Pediatric Surgery at Rikshospitalet (1975-1976) 🇳🇴 and Children’s Hospital of Los Angeles (1976-1978) 👶🩺.

Experience

Dr. Michael Harrison 🏥 has been a Founding Member of the International Fetal Medicine and Surgery Society (1981-present) 👶 and has served as its President at the Annual Meeting (1989, 2006) 🎤. He has contributed as a Committee Member for the Medical Advisory Committee of the American Association of Tissue Banks (1993-present) 🧬 and chaired the Committee on Fetal Therapy at APSA (1994-1996) 🏥. A Board Member of the International Society of the Fetus as Patient (1997-present) 🌍, he also consults for the MOMS study (2003-present) 🤰. Since 2010, he has been Vice President of the California Academy of Medicine 📚.

Awards

Dr. Michael Harrison 🏅 has received numerous prestigious honors, including the Golden Plate Award (1982, 1988) 🏆, the William E. Ladd Medal (2010) 🏅, and the Lifetime Achievement Award (2011) 🌟 from the International Fetal Medicine and Surgery Society. He was elected to the Institute of Medicine (2009) 📜 and honored with the Denis Browne Gold Medal (2013) 🏵️. As a celebrated lecturer, he has delivered keynote addresses worldwide 🌍, including at the Nobel Minisymposium on Fetal Medicine (1998) 🎤. His groundbreaking contributions in pediatric surgery have earned him global recognition and lasting influence in the field.

Research Focus

Dr. Michael R. Harrison is a pioneering surgeon and researcher in pediatric surgery and fetal therapy 🏥👶. His work focuses on maternal-fetal surgery, particularly for conditions like esophageal atresia and diaphragmatic hernia. He has contributed to the development of magnetic compression anastomosis 🧲 and other innovative minimally invasive surgical devices 🔬. His research advances the treatment of complex congenital disorders and improves outcomes for newborns. With numerous publications, he has significantly impacted pediatric device clinical trials 📊. Dr. Harrison’s groundbreaking contributions continue to shape the future of pediatric and fetal surgical care 🚼✨.

Publication Top Notes

Pediatric Device Clinical Trials Activity: 1999–2022

Lessons Learned From the First-In-Human Compassionate Use of Connect-EA™ in Ten Patients With Esophageal Atresia

Evaluation of a Magnetic Compression Anastomosis for Jejunoileal Partial Diversion in Rhesus Macaques

Sonographic Predictors of Survival in Fetal Diaphragmatic Hernia

Beyond the gut: spectrum of magnetic surgery devices

The Rearing of Maternal–Fetal Surgery: The Maturation of a Field from Conception to Adulthood

The novel application of an emerging device for salvage of primary repair in high-risk complex esophageal atresia

Esophageal Magnetic Compression Anastomosis in Esophageal Atresia Repair: A PRISMA-Compliant Systematic Review and Comparison with a Novel Approach

An experimental study on long term outcomes after magnetic esophageal compression anastomosis in piglets

Novel device for endoluminal esophageal atresia repair: First-in-human experience

Dr. Alberto Camacho Morales|Personalized Medicine|Excellence in Researchd

Published on by Top Pharmaceutical

Dr. Alberto Camacho Morales|Personalized Medicine|Excellence in Research

Dr. Alberto Camacho Morales at Abdul wali khan university mardan,Pakistan

PROFILE  

 

Google scholar

Orcid

scopus.

Early Academic Pursuits 🎓

Alberto Camacho Morales’s academic journey is a testament to his dedication to biomedical sciences. After earning a Bachelor’s degree in Biology from the Faculty of Sciences at the National Autonomous University of Mexico (UNAM) in 1999, he pursued advanced studies with unwavering focus. Driven by a passion for understanding cellular processes, he completed a Ph.D. in Biomedical Sciences at the Institute of Cellular Physiology (UNAM) in 2007. His doctoral research laid a strong foundation for his specialization in metabolic and neurophysiological sciences. Alberto’s pursuit of academic excellence culminated in a postdoctoral fellowship at the Institute of Metabolic Science, University of Cambridge, England (2007–2011). These experiences solidified his expertise in metabolic programming, a field where he has become a pioneering voice.

Professional Endeavors 🏢

Since completing his postdoctoral studies, Dr. Camacho Morales has held several influential roles in academia and research. He began his teaching career as a professor-researcher at the School of Medicine, Tecnológico de Monterrey (2011). By 2012, he transitioned to the Faculty of Medicine, Autonomous University of Nuevo León (UANL), where he assumed roles that included leading molecular and biochemical studies and coordinating critical academic programs for graduate and undergraduate students.

Dr. Camacho has also extended his expertise beyond academia as a President and Member of Biosecurity and Research Committees at Accelerium Clinical Research, a testament to his ability to bridge research and its practical applications in clinical settings. His 17+ years of professional experience in translational science have equipped him to consult and guide preclinical and clinical research projects effectively.

Contributions and Research Focus 🧠

Dr. Camacho Morales’s research contributions have significantly impacted the understanding of metabolic disorders and neurophysiological programming. His primary areas of research include:

Maternal Neuroinflammation and Behavioral Disorders: Investigating how maternal obesity during pregnancy programs neuroinflammation, contributing to behavioral abnormalities in offspring.
Neuronal Plasticity and Addiction: Understanding the role of neuronal plasticity in hypercaloric food addiction and its implications in obesity development.
Metabolic Programming During Pregnancy: Exploring how prenatal metabolic programming influences metabolic and behavioral outcomes in offspring.
Biomarkers of Metabolic Damage: Identifying blood biomarkers associated with metabolic damage in obese individuals, with and without Type 2 diabetes.
Dr. Camacho’s research combines cutting-edge methodologies in molecular biology, neuroscience, and endocrinology, addressing global challenges like obesity, diabetes, and neuropsychiatric disorders.

Accolades and Recognition 🏆

Dr. Camacho Morales’s exemplary work has earned him numerous awards and recognitions:

National Researcher Level III (2024): A prestigious distinction from Mexico’s National System of Researchers.
First Place in Basic Science Research (2023): UANL acknowledged his groundbreaking work in metabolic programming.
Multiple accolades at state and national levels, including awards in research competitions (e.g., Funsalud Prize for Basic Research in 2018).
Marie Curie Postdoctoral Fellowship: A two-year fellowship at the University of Cambridge, funded by the European Union.
His sustained commitment to scientific excellence is also evident in his editorial roles for esteemed journals like Frontiers in Endocrinology and Molecular Psychiatry.

Impact and Influence 🌍

As a leader in his field, Dr. Camacho Morales has made significant contributions to the academic community. His roles as a professor and mentor at UANL have inspired countless students to pursue careers in biomedical sciences. He coordinates critical courses in molecular biology, biochemistry, and cellular biology for master’s and doctoral programs, shaping future researchers’ perspectives.

His editorial and peer-review roles for high-impact journals, such as Diabetes and Molecular Neuroscience, demonstrate his influence in advancing global biomedical research. By reviewing and editing scientific literature, he has contributed to the integrity and progression of his field.

Legacy and Future Contributions 🌱

Dr. Camacho Morales’s work has lasting implications for understanding and treating metabolic and neurophysiological disorders. His research on the programming of metabolic and behavioral outcomes in offspring provides valuable insights for developing preventive and therapeutic strategies.

 

🎓Publication 

Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice

  • Authors   : Xavier Prieur, Crystal YL Mok, Vidya R Velagapudi, Vanessa Núñez, Lucía Fuentes, David Montaner, Ko Ishikawa, Alberto Camacho, Nuria Barbarroja, Stephen O’Rahilly, Jaswinder K Sethi, Joaquin Dopazo, Matej Orešič, Mercedes Ricote, Antonio Vidal-Pui
  • Journal    :American Diabetes Association
  • Year         :2011

Role of glutamate transporters in the clearance and release of glutamate during ischemia and its relation to neuronal death

    • Authors   : Alberto Camacho, Lourdes Massieu
    • Journal    : Archives of medical research
    • Year         :2006

Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum

  • Authors   : Erika Rodrı́guez-Martı́nez, Alberto Camacho, Perla D Maldonado, José Pedraza-Chaverrı́, Daniel Santamarı́a, Sonia Galván-Arzate, Abel Santamarı́a
  • Journal    : Brain research
  • Year         :2000

In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum

  • Authors   :Abel Santamaría, María E Jiménez-Capdeville, Alberto Camacho, Erika Rodríguez-Martínez, Abigail Flores, Sonia Galván-Arzate
  • Journal     :Neuroreport
  • Year         :2001

Microglia activation due to obesity programs metabolic failure leading to type two diabetes

  • Authors   : R Maldonado-Ruiz, L Montalvo-Martínez, Lizeth Fuentes-Mera, A Camacho
  • Journal    : Nutrition & diabetes
  • Year         :2017